Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aytu BioScience Inc (AYTU)
NASDAQ:AYTU
Holding AYTU?
Track your performance easily
AYTU Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.41 - $3.45
Previous Close$1.63
Volume69.79K
Average Volume (3M)28.77K
Market Cap
$10.02M
Enterprise Value$6.47M
Total Cash (Recent Filing)$20.11M
Total Debt (Recent Filing)$16.56M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Feb 12, 2025EPS Estimate
-$0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.22
Shares Outstanding6,149,369
10 Day Avg. Volume63,792
30 Day Avg. Volume28,771
Standard Deviation0.31
R-Squared0.06
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.31
Price to Sales (P/S)0.13
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.09
Enterprise Value/Gross Profit0.12
Enterprise Value/Ebitda1.27
Forecast
1Y Price Target
$8.00Price Target Upside409.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Aytu BioScience News
PremiumCompany Announcements
Aytu BioPharma Reports Q1 Fiscal 2025 Earnings
PremiumCompany Announcements
Aytu BioScience Announces Leadership Change and Financial Growth
PremiumCompany Announcements
Aytu BioScience Expands ADHD Portfolio into Canada
PremiumCompany Announcements
Aytu BioScience Divests Consumer Health BusinessBulls Say, Bears Say
Bulls Say
Financial PerformanceAytu experienced its first quarter of net income profitability due to improved operations and financial performance.
Revenue DiversificationAytu BioPharma, Inc. signs commercialization agreement for Canada, diversifying revenue stream in future years.
Strategic PartnershipsAytu announced an exclusive agreement with Lupin Pharma Canada to commercialize Adzenys XR-ODT and Cotempla XR-ODT in Canada, with minimal cost to Aytu, ensuring most revenue will be pure margin.
Bears Say
Financial ResultsF4Q Miss
Market PerformanceThe stimulant shortages appear to be less challenging than previous years, which is believed to have led to slowdowns in the ADHD franchise growth.
Product DemandThe stimulant shortages have ameliorated slightly, leading to slowdowns in ADHD franchise growth as some patients returned to prior therapies.
---
Ownership Overview
8.19% Insiders
1.19% Mutual Funds
29.66% Other Institutional Investors
60.39% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
AYTU FAQ
What was Aytu BioScience Inc’s price range in the past 12 months?
Aytu BioScience Inc lowest stock price was $1.41 and its highest was $3.45 in the past 12 months.
What is Aytu BioScience Inc’s market cap?
Currently, no data Available
When is Aytu BioScience Inc’s upcoming earnings report date?
Aytu BioScience Inc’s upcoming earnings report date is Feb 12, 2025 which is in 78 days.
How were Aytu BioScience Inc’s earnings last quarter?
Aytu BioScience Inc released its earnings results on Nov 13, 2024. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.34 by $0.14.
Is Aytu BioScience Inc overvalued?
According to Wall Street analysts Aytu BioScience Inc’s price is currently Undervalued.
Does Aytu BioScience Inc pay dividends?
Aytu BioScience Inc does not currently pay dividends.
What is Aytu BioScience Inc’s EPS estimate?
Aytu BioScience Inc’s EPS estimate is -$0.28.
How many shares outstanding does Aytu BioScience Inc have?
Aytu BioScience Inc has 6,149,369 shares outstanding.
What happened to Aytu BioScience Inc’s price movement after its last earnings report?
Aytu BioScience Inc reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.34. Following the earnings report the stock price went down -10.92%.
Which hedge fund is a major shareholder of Aytu BioScience Inc?
Currently, no hedge funds are holding shares in AYTU
---
Aytu BioScience Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (409.55% Upside)
$8.00 (409.55% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 7.6%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.05%
12-Months-Change
Fundamentals
Return on Equity
-21.39%
Trailing 12-Months
Asset Growth
-12.84%
Trailing 12-Months
Company Description
Aytu BioScience Inc
Aytu BioScience, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. Its products include Natesto, Tuzistram, ZolpiMist and MiOXSYS. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.
---
AYTU Earnings Call
Q1 2024
0:00 / 0:00
---
AYTU Stock 12 Month Forecast
Average Price Target
$8.00
▲(409.55% Upside)
Technical Analysis
Best Analysts Covering AYTU
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-22.21%
reiterated a buy rating 12 days ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -22.21% per trade.
---